Fresh analysis reveals that people who stop using new weight-loss injections like Mounjaro or Wegovy tend to recover shed pounds far faster than those who end traditional lifestyle programs.
Research printed in a major health publication points out that while obese individuals often shed substantial amounts of their body weight while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month once they quit.
"Individuals purchasing such treatments need to be informed of the danger of fast rebound weight gain when the treatment is stopped," stated expert Dr. Susan Jebb.
Such speed of regain implies a reversion to starting weight within about 18 months.
Weighing Approaches
The research, which looked at dozens of trials involving thousands of patients, contrasted the effects of GLP-1 agonists with other pills.
The team emphasize that individuals who lose weight through lifestyle changes alone typically have a slower creep back—approximately 100 grams monthly—once they finish.
Understanding the Quick Regain
Experts propose the mechanism of the jabs accounts for the heightened rebound.
These medications mimic a body's own chemical called GLP-1, which moderates feelings of fullness.
"Sustained high doses of the hormone concentrations far above than normal may cause the body to generate a reduced amount of its endogenous hormone, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement leads to appetite is no longer kept in check, making overeating a significant risk."
A Chronic Disease?
Health authorities recommend the jabs for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians contend that, given the likelihood of relapse, the therapy might need to be long-term.
This opinion is echoed by pharmaceutical companies, who state that the findings "emphasize the persistent character of obesity," similar to managing diseases like hypertension.
Patient Experiences
People who have discontinued the jabs report a intense resurgence of hunger.
"It felt as if a trigger that goes on and you're instantly ravenous," said a patient.
This difficulty is worsened if patients have not established permanent dietary or behavioural changes during treatment.
Significant Adoption
Survey data show that a significant number of people in the UK have tried these injections in the last 12 months, with desire being substantial.
- Use is more common among females than men.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
Finally, researchers emphasize that while GLP-1 drugs are powerful tools for shedding pounds, they are not a magic solution and long-term success relies on integrated lifestyle changes.
